How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks? Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the stock’s prospects Barchart · May 31
Igor Taldenko: "A Website Outage Today Is an Event That Affects People's Lives" An engineer with over 12 years of experience working with high-load systems explains why a website outage is no longer just a bug — it's an event capable of derailing transactions, delaying payments, and even impacting people's health — and how to build architecture that minimizes these risks. inkl · May 28
3 Dividend Stocks Yielding Above 5% to Scoop Up Now These three dividend stocks combine strong yields with resilient businesses. Barchart · May 26
False claims link hantavirus to COVID vaccines Social media users are claiming that hantavirus was listed as a side effect of the COVID-19 vaccine, but that's a misreading of the facts. AAP · May 22
Lyme disease cases in England rise by more than 20% in a year Scientists developing vaccines and anti-tick treatments amid growing concern over spread of disease The Guardian - UK · May 21
Debunked Bill Gates tick theory resurfaces through MAHA social media claims IN FULL The Independent UK · May 20
MAHA’s latest conspiracy? Blaming Bill Gates for spike in tick bites The number of tick-related visits to emergency rooms has hit the highest level in the U.S. in nearly a decade The Independent UK · May 19
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2 MarketBeat · May 15
Valneva Q1 Earnings Call Highlights Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach MarketBeat · May 13
Arvinas Q1 Earnings Call Highlights Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation. President and Chief Executive Officer Randy Teel said the app MarketBeat · May 12
White House Says Trump's Drugmaker Deals Could Save U.S. Economy $529 Billion Over 10 Years The White House said on Tuesday that agreements with major drugmakers could save the U.S. economy $529 billion over the next decade. International Business Times · May 5
Stock Index Futures Climb as U.S.-Iran Ceasefire Holds, JOLTs Report and Earnings in Focus June S&P 500 E-Mini futures (ESM26) are up +0.28%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.47% this morning, supported by lower oil prices as the ceasefire in the Middle East appeared to be holding. Barchart · May 5
Are Wall Street Analysts Bullish on Pfizer Stock? Pfizer has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects. Barchart · Apr 28
Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story. A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside. Barchart · Apr 24
Reason · Apr 21 The COVID Reckoning Doesn't Go Far Enough Real medical freedom will require something greater than replacing the public health establishment: ending the FDA's monopoly.
The Guardian - US · Apr 20 Will RFK Jr’s podcast actually address Americans’ public health concerns? Secretary Kennedy Podcast so far seems designed to promote Trump administration talking points over any specific public health message
Barchart · Apr 14 Earnings Preview: What to Expect From Pfizer’s Report Pfizer is set to report its first-quarter earnings next month, with analysts expecting profits to decline in the low double-digit range.
The Times of India · Apr 13 Elon Musk reveals he ‘felt like he was dying’ after a COVID vaccine shot; says the virus was just a bad cold Tech mogul Elon Musk sparked global vaccine debate by sharing his severe reaction to a COVID-19 vaccine dose, contrasting it with a mild virus infection. His remarks followed testimony by a former Pfizer toxicologist raising concerns about vaccine safety. Health authorities, however, continue to affirm the vaccines' safety and efficacy…
Fortune · Apr 3 Only one U.S. university ranks in the world’s top 10 in STEM. Pfizer’s CEO is calling for change Pfizer CEO Albert Bourla warns U.S. and European universities are falling behind as Chinese institutions surge ahead in research output: “We need to become better.”
The Mary Sue · Apr 1 He knows the pain of Lyme disease better than anyone, but RFK Jr. is about to make a decision that has health experts terrified Here’s some big news in the fight against Lyme disease: Pfizer just announced its plan to file for regulatory approval of a new Lyme disease vaccine. If it gets the green light, this would be the first vaccine for the tick-borne illness available in over two decades. This new development,…
International Business Times · Mar 31 Pfizer Stock Edges Higher as Oncology Wins and Pipeline Bets Fuel Optimism Amid Flat 2026 Outlook Pfizer Inc. shares ticked up modestly Tuesday as investors weighed fresh positive oncology data against the pharmaceutical giant's flat revenue guidance for 2026 and ongoing pressures from declining COVID-19 product sales.
MarketBeat · Mar 23 5 High-Yield Stocks to Shield Your Portfolio From the Storm With the S&P 500 breaking below its 200-day SMA, high-yield dividend stocks are increasingly worth considering as a source of income and portfolio protection.
Euronews · Mar 23 Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial Pfizer and Valneva's Lyme disease vaccine has shown promising results in clinical trials, paving the way for regulatory approval despite setbacks due to fewer cases than expected, according to the companies.
Barchart · Mar 19 Follow the Footprints: 3 Stocks with Unusual Options Activity That You Can’t Ignore On a day when nothing worked for investors, yesterday’s unusual options activity had plenty of variety, especially in the top three. Here’s how investors might have played each of the stock's and their options.
Barchart · Mar 19 Looking for Safety and Yield as Oil Prices Whip Saw? This Stock Has You Covered. As oil prices rise with increasing global uncertainty, this pharmaceutical stock emerges as a possible safe haven for income investors.